F Y Yao

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
    F Y Yao
    Department of Transplantation, California Pacific Medical Center, San Francisco 94143 0538, USA
    J Hepatol 33:301-7. 2000
  2. ncbi request reprint Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging
    F Y Yao
    Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
    Am J Transplant 7:2587-96. 2007
  3. ncbi request reprint A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation
    Francis Y Yao
    Department of Medicine, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0538, USA
    Liver Transpl 11:1505-14. 2005
  4. ncbi request reprint The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma
    Francis Y Yao
    Department of Medicine, University of California, San Francisco, CA, USA
    Am J Transplant 5:795-804. 2005
  5. ncbi request reprint Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy
    Francis Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, 94143 0538, USA
    Liver Transpl 10:621-30. 2004
  6. ncbi request reprint A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy
    Francis Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco 94143, USA
    Liver Transpl 9:684-92. 2003
  7. ncbi request reprint Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis
    Francis Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco 94143, USA
    J Clin Gastroenterol 36:440-2. 2003
  8. ncbi request reprint Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list
    Francis Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA 94143 0538, USA
    Liver Transpl 8:873-83. 2002
  9. ncbi request reprint Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival
    F Y Yao
    Department of Medicine, University of California, San Francisco 94143 0538, USA
    Hepatology 33:1394-403. 2001
  10. ncbi request reprint Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria
    Francis Y Yao
    Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143 0538, USA
    Liver Transpl 8:765-74. 2002

Detail Information

Publications26

  1. ncbi request reprint Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
    F Y Yao
    Department of Transplantation, California Pacific Medical Center, San Francisco 94143 0538, USA
    J Hepatol 33:301-7. 2000
    ..The aim of this study was to evaluate the effectiveness of lamivudine treatment in severely decompensated cirrhosis due to chronic hepatitis B...
  2. ncbi request reprint Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging
    F Y Yao
    Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
    Am J Transplant 7:2587-96. 2007
    ....
  3. ncbi request reprint A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation
    Francis Y Yao
    Department of Medicine, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0538, USA
    Liver Transpl 11:1505-14. 2005
    ..3 and 81.8% at 1 and 2 yr, respectively. In conclusion, successful tumor downstaging can be achieved in the majority of carefully selected patients, but longer follow-up is needed to further access the risk of HCC recurrence after OLT...
  4. ncbi request reprint The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma
    Francis Y Yao
    Department of Medicine, University of California, San Francisco, CA, USA
    Am J Transplant 5:795-804. 2005
    ....
  5. ncbi request reprint Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy
    Francis Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, 94143 0538, USA
    Liver Transpl 10:621-30. 2004
    ..Compared with preliminary UNOS data, in which 90% of patients with HCC have received OLT within 3 months, our results reflect the wide regional variation in the impact of MELD...
  6. ncbi request reprint A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy
    Francis Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco 94143, USA
    Liver Transpl 9:684-92. 2003
    ..004). In conclusion, the low dropout rate in the first 6 months and the differing dropout risks based on tumor characteristics support further refinements in the HCC-adjusted MELD organ allocation scheme...
  7. ncbi request reprint Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis
    Francis Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco 94143, USA
    J Clin Gastroenterol 36:440-2. 2003
    ..These observations may be helpful in the diagnostic evaluation and management of patients with markedly elevated alpha-fetoprotein levels and chronic hepatitis B-related cirrhosis...
  8. ncbi request reprint Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list
    Francis Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA 94143 0538, USA
    Liver Transpl 8:873-83. 2002
    ..Our results support recent changes in the scheme of organ allocation aimed at reducing the dropout rate and improving outcome for patients with HCC awaiting OLT...
  9. ncbi request reprint Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival
    F Y Yao
    Department of Medicine, University of California, San Francisco 94143 0538, USA
    Hepatology 33:1394-403. 2001
    ..0005). We conclude that the current criteria for OLT based on tumor size may be modestly expanded while still preserving excellent survival after OLT...
  10. ncbi request reprint Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria
    Francis Y Yao
    Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143 0538, USA
    Liver Transpl 8:765-74. 2002
    ..UCSF criteria confer a different advantage over Pittsburgh criteria, which require information on microvascular invasion that is difficult to ascertain preoperatively without the attendant risk of biopsy...
  11. ncbi request reprint Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort
    F Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA 94143 0538, USA
    Hepatology 34:411-6. 2001
    ..However, the small sample size and the use of a retrospective control cohort preclude drawing definitive conclusions. Expedited OLT remains the only viable treatment for lamivudine nonresponders...
  12. doi request reprint Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria
    F Y Yao
    Division of Gastroenterology, University of California, San Francisco, CA 94143 0538, USA
    Am J Transplant 8:1982-9. 2008
    ....
  13. ncbi request reprint Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma
    S D Chao
    Departments of Surgery, University of California, San Francisco, CA, USA
    Am J Transplant 7:1594-600. 2007
    ....
  14. doi request reprint Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation
    A James Hanje
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California 94143 0538, USA
    Curr Opin Organ Transplant 13:234-40. 2008
    ..This article reviews the principles and published data on down-staging of hepatocellular carcinoma prior to orthotopic liver transplantation...
  15. doi request reprint Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis
    Francis Y Yao
    Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
    Hepatology 48:819-27. 2008
    ..2% and 92.1%, respectively. No patient had HCC recurrence after a median posttransplantation follow-up of 25 months. The only factor predicting treatment failure was pretreatment alpha-fetoprotein >1,000 ng/mL...
  16. ncbi request reprint Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis
    Derek Patel
    Division of Gastroenterology, Department of Medicine, University of California, 513 Parnassus Avenue, San Francisco, CA 94143 0538, USA
    Clin Gastroenterol Hepatol 3:75-84. 2005
    ..Surveillance might detect HCC at a treatable stage. We estimated the clinical and economic consequences of a common HCC surveillance strategy in patients with HCV-related cirrhosis in the context of alternative HCC treatment strategies...
  17. ncbi request reprint Expanded criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation--yes
    Francis Y Yao
    University of California, San Francisco, CA 94143 0538, USA
    Semin Liver Dis 26:239-47. 2006
    ..The promise of down-staging warrants consideration of a unified policy granting patients with HCC that has been successfully down-staged the same priority listing for OLT as those meeting conventional criteria...
  18. ncbi request reprint Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores
    Francis Y Yao
    Department of Medicine University of California, San Francisco, San Francisco, CA, USA
    Hepatology 39:230-8. 2004
    ..In conclusion, our results suggest that severity of graft failure based on CTP and MELD scores may be associated with worse outcome after re-OLT and provide a cautionary note for the "sickest first" policy of organ allocation...
  19. ncbi request reprint The role of the interventional radiologist. Transjugular procedures
    N M Bass
    Liver Transplant Program, Division of Gastroenterology and Liver Transplant Program, University of California, San Francisco, San Francisco, California 94143-0538, USA
    Gastrointest Endosc Clin N Am 11:131-61. 2001
    ..This article reviews the current techniques, indications, and complications of these interventional procedures and their role in the management of patients with end-stage liver disease...
  20. ncbi request reprint De novo non-alcoholic fatty liver disease following orthotopic liver transplantation
    Fred Poordad
    Department of Transplantation, California Pacific Medical Center, San Francisco, USA
    Am J Transplant 3:1413-7. 2003
    ..NAFLD can develop without any of the known predisposing conditions after transplantation, and this raises further questions about the pathogenesis of this condition...
  21. ncbi request reprint De novo malignancies following liver transplantation: a case-control study with long-term follow-up
    Francis Y Yao
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0538, USA
    Clin Transplant 20:617-23. 2006
    ..Long-term survival data on de novo malignancy are limited following orthotopic liver transplantation (OLT) when compared with controls without malignancies...
  22. ncbi request reprint High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome
    Elizabeth Cruz
    Division of Gastroenterology, Department of Medicine, University of California, San Francisco, CA 94143 0538, USA
    Clin Transplant 19:501-6. 2005
    ..We evaluated the long-term outcome, risks for recurrent disease, and other hematologic complications following orthotopic liver transplantation (OLT) for BCS...
  23. ncbi request reprint Liver transplantation for hepatocellular carcinoma: the hepatitis C quandary
    Francis Y Yao
    Liver Transpl 13:783-5. 2007
  24. ncbi request reprint Selection criteria for liver transplantation in patients with hepatocellular carcinoma: beyond tumor size and number?
    Francis Y Yao
    Liver Transpl 12:1189-91. 2006
  25. pmc Liver transplantation for hepatocellular carcinoma
    Vincenzo Mazzaferro
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 15:1001-7. 2008
    ....
  26. ncbi request reprint Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?
    Francis Y Yao
    Liver Transpl 10:919-21. 2004